Certain dibenzo(b,f)thiepin(4,5-d) imidazoles

ABSTRACT

2-SUBSTITUTED DIBENZO(B,F)THIEPIN(4,5-D)- AND DIBENZO(3,4,7,8)CYCLOOCTA(1,2-D)IMIDAZOLES AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, A NOVEL CLASS OF ANTI-INFLAMMATORY AGENT.

Patented Dec. 25, 1973 Y X Y 3,781,294 I CERTAIN DIBENZO[b,f]THIEPIN[4,5-d] x IMIDAZOLES Joseph G. Lombardino, East Lyme, Conn., assignor to Pfizer Inc., New York, N.Y. No Drawing. Original application Mar. 31, 1971, Ser. No. 129,977, now Patent No. 3,711,489. Divided and this application July 31, 1972, Ser. No. 276,597

Int. Cl. C07d 31/40, 49/36 CL A 6 Claims 10 wherein Z, X, Y and R are as previously mdlcated and R is lower alkyl. ABSTRACT OF THE DISCLOSURE DETAILED DESCRIPTION OF THE INVENTION 2-substituted dibenzo[b,f]thiepin[4,5-d]- and dibenzo- In accordance with the process for preparing the tetra- [3,4,7,8]cyclo6cta[1,2-d] imida l nd th h cyclicimidazoles of the present invention of Formula I:

ceutically acceptable acid addition salts thereof, a novel 2 class of anti-inflammatory agent.

CROSS REFERENCE TO RELATED APPLICATION 0 This application is a division of application Ser. No. N NH 129,977, filed Mar. 31, 1971, now U.S. Pat. 3,711,489.

BACKGROUND OF THE INVENTION This invention relates to tetracyclic imidazoles, and more particularly to a series of 2-substituted dibenzo Whemin Y and R are as Prevlously lndlcated, the [b,f]thiepin[4,5-d]- and dibenzo[3,4,7,8]cycloticta[1,2- following Scheme is illustrativm d]imidazoles and their pharmaceutically acceptable acid gddition salts as a novel class of anti-inflammatory agents.

ynthesis of these compounds is achieved through a condensation of the requisite a-diketone, an aldehyde and X I Y ECHO CHaCOzNH I ammonium acetate.

References directed toward polycyclicimidazoles are not common in the chemical literature; Steck and Day,

Chem 452 (1943) in an effort to The above illustrated reaction is conducted under retermine the course of the reaction involved in imidazole action condltlons which are essentially those as employed formation synthesized a series of phenanthrimidazoles. by Davidson et all, J. Org. Che 2 319 (1937), d

No utility, however, was disclosed for these compounds. comprises heating a mixture of an wdiketone, an alde SUMMARY OF THE INVENTON hyde or derivative thereof and ammonium acetate in a h tetracyclic ti i fl t agents of this invem solvent of glacial acet c acid. As much as a five to ten tion are represented by the formula. fold excess of ammonium acetate can be employed. The amount of aldehyde used in relation to the diketone can vary from an equimolar amount to as much as a 100% X Y excess.

In general, reflux temperatures are considered desirable W although lower temperatures with correspondingly longer reaction periods are operable. When said reflux temperatures are employed reaction times of -l2 hours are adequate to yield the desired product.

R A convenient method for isolation of the product comand the pharmaceutically acceptable acid addition salts prises dilution of the ac mi Xtl1re Wlth water followed thereof, where: by neutralization with ammomum hydroxide to a pH of approximately 7. The resulting precipitate is then filtered, dried and recrystallized from an appropriate solvent. X and Y are each hydrogen methyl methoxy fluonne The requisite a-diketones wherein X and Y are as dechlorine bromine or methylthio' and fi ned and Z is ethylene are synthesized according to the R mfiuoromethyl pyndyl naphthyl. or phepyl or method as taught by Leonard et al., J. Am. Chem. Soc., Stunted Phenyi Where subsilmeni 1S h 77, 507s 1955). Further, a-diketones wherein X and Y methoxy fluonne chlonne bromine dunethylammo are as indicated and Z is sulphur are prepared by selenium carboxy or methylthlo' dioxide oxidation of the corresponding monoketones Of particular interst are congeners wherein Z is ethylwhich, in turn, are made according to the procedure as ene, X and Y are hydrogen and R is phenyl, 3-pyridyl or taught by Jilek et al., Monatsh. Chem., 96, 201 (1965). trifluoromethyl, and those wherein Z is sulphur, X and The appropriate aldehydes are either commercially avail- Y are hydrogen and R is p-methoxyphenyl, 3-pyridyl, able or easily prepared by one skilled in the art according trifluoromethyl or p-carboxyphenyl. to the methods as outlined by Carnduif, Quart. Rev., 20,

Also included within the scope of the present invention 169 (1966). are the sulfoxides and sulfones of those analogs wherein A characteristic of the compounds of the present inven- Z is sulphur, congeners wherein R is lower alkyl and, tion is the acidic nature of the imidazole hydrogen and finally, alkylation products of the compounds of the the property to form salts with basic reagents such as present invention wherein said products are represented alkali metal hydroxides, alkoxides or hydrides and alkali by the formulae: earth metal hydroxides.

It is these above described basic salts which can be alkylated giving rise to the compounds related to 'I where the imidazole hydrogen is replaced by R which is lower alk 1.

l egarding alkylation, the imidazoles of the above formulae where R is hydrogen are equivalent because of the tautomeric nature of the acidic hydrogen as illustrated.

N NH

HN N

However, once alkylation has been carried out on the imidazole, tautomerization through migration of the alkyl group is impossible. A more detailed discussion of this concept is provided by Schipper et al., Heterocyclic Compounds, vol. V, R. C. Elderfield, ed., John Wiley & Sons, Inc., New York, NY. (1957), chapter 4, page 198.

Thus, during alkylation of the imidazoles it can be noted that two positional isomers are frequently formed due to the difference in the nature of the X and Y substituents.

In the case of such experimental results, the mixture of isomers is recovered by methods known to those skilled in the art. In many of the preparations disclosed wherein a solid, often crystalline material, separates from the reaction mixture, the solid appears to consist predominantly of one of the isomers. Said isomer can be purified by repeated recrystallization from a suitable solvent to a constant melting point. The other isomer, the one present in smaller amounts in the originally isolated solid material, is the predominant product in the mother liquor. It can be recovered therefrom by methods known to those skilled in the art, as for example, the evaporation of the mother liquor and repeated crystallization of the residue to a product of constant melting point. Alternatively, the reaction mixture can be extracted either before or after evaporation to dryness.

Although said mixtures may be separated by methods known to those skilled in the art, for practical reasons it is advantageous to use said mixtures as they are isolated from the reaction. Further, it is frequently advantageous to purify these mixtures of isomers by at least one recrystallization from an appropriate solvent or by trituration in an appropriate solvent. Said recrystallization or trituration thus allows the separation of the mixture of positional isomers from such extraneous materials as starting material and undesirable by-products.

The identification of the isomers has not been completed. Both isomers of a given compound, however, exhibit the same type of activity, e.g., as anti-inflammatory agents.

Experimentally, a solution of the unalkylated imidazole in a highly polar, aprotic solvent such as dimethyl formamide, dimethylsulfoxide, or hexamethylphosphoramide is treated with at least an equivalent amount of an alkali metal alkoxide or hydride such as sodium methoxide or sodium hydride, thus forming the corresponding sodium salt in situ. The alkyl halide, either chloride, bromide, or iodide, is added, usually in an aprotic solvent, to ,the

solution or suspension of the requisite salt of the imidazole. At least an equimolar amount of alkylating agent 1s added, plus as much as a 10-50% excess.

Reaction temperatures are not critical, but for convenience the reaction mixture is heated at steam bath temperatures for 1-5 hours. Following the completion of the reaction, the product or products are isolated andpurified as disclosed above.

As has been previously mentioned, the compounds of the present invention, in addition to forming salts with basic reagents, can also, as previously mentioned, form acid addition salts. Said compounds of the present invention are converted to the acid addition salts by interaction of the base with an acid either in an aqueous or nonaqueous medium. In a similar manner, treatment of the acid addition salts with an equivalent amount of an aqueous base solution, e.g., alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates or with an equivalent amount of a metal cationwhich forms an insoluble precipitate with the acid anion, results in a regeneration of the free base form. Such conversions are best carried out as rapidly as possible and under temperature conditions and method dictated by the stability of said basic products. The bases thus regenerated may be reconverted to the same or a different acid addition salt.

In the utilization of the chemotherapeutic activity of those compounds of the present invention which form salts, it is preferred, of course, to use pharamceutically acceptable salts. Although water-insolubility, high toxicity, or lack of crystalline nature may make some particular salt species unsuitable or less desirable for use as such in a given pharmaceutical application, the water insoluble or toxic salts can be converted to the corresponding pharmaceutically acceptable bases by decomposition of the salt as described above, or alternately they can be converted to any desired pharmaceutically acceptable acid addition salt.

Examples of acids which provide pharmaceuticaHy acceptable anions are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, or sulfurous, phosphoric, acetic, lactic, citric, tartaric, succinic, maleic, and gluconic acids.

As previously indicated, the tetracyclicirnidazoles of the present invention are all readily adapted to therapeutic use as anti-inflammatory agents in mammals. Outstanding for their effectiveness in this regard are the following agents: 8,9-dihydro 2 phenyldibenzo[3,4,7,8]cycloocta [l,2-d]imidazole (I: Z=CH CH X, Y=H and R=), 8,9-dihydro-2-(3-pyridyl)-dibenzo[3,4,7,8]cyclo- 6cta[1,2-d]imidazole (I: Z=-CH CH X, Y=H and R=3-pyn'dyl) 8,9-dihydro-2-trifluoromethyldibenzo [3,4, 7,8]cyclo6cta[l,2-d]imidazole (I: Z=CH CH X, Y=H and R=CF Z-tri-fiuoromethyldibenzo[b,f] thiepin [4,5-d1imidazole (I: Z=S; X, Y=H and R=CF 2-(pmethoxyphenyl) dibenzo [b,f] thiepin [4,5-d1imidazole (1: 2:8; X, Y=H and R=p-CH OC H 2-(3-pyridyl)- dibenzo[b,f]thiepin[4,5-d]imidazole (1: 2:8; X, Y=H and R=3-pyridyl) and 2-(p-carboxyphenyl)dibenzo[b,f] thiepin[4,5 d]imidazole (I: Z='S; X, Y=H and R=P'HOZCC5H4) A standard procedure for detecting and comparing anti-inflammatory activity of compounds in this series and for which there is an excellent correlation with human efficacy is the carrageenin rat foot edema test of Winter et al., Proc. Soc. Exp. Biol., 111, 544 (1962), whereby unanesthetized adult albino rats of 150-190 g. body weight are each numbered, weighed and marked with ink on the right lateral malleolus. One hour after administration of the drug by gavage, edema is induced by injection of 0.05 ml. of 1% solution of carrageenin into the plantar tissue of the marked paws. Immediately there-.- after, the volume of the injected paw is measured. The increase in volume three hours after the injection of carrageenin constitutes the individual response. Compounds are considered active if the difference in response between a control and the drug being tested is significant. Standard compounds are phenylbutazone at 33 mg./kg. and acetylsalicylic acid at mg./kg., both with oral administration.

The tetracyclicimidazoles and the pharmaceutically acceptable salts thereof, which were useful anti-inflammatory agents, may be administered either as individual therapeutic agents or as mixtures of therapeutic agents. They may be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar or certain types of clay, etc. They may be administered orally in the form of elixirs or oral suspensions with the active ingredients combined with emulsifying and/or suspending agents. They may be injected parenterally, and for this use they, or appropriate derivatives, may be prepared in the form of sterile aqueous solutions. Such aqueous solutions should be suitably buffered, if necessary, and should contain other solutes such as saline or glucose to render them isotonic.

Although the use of the present invention is directed toward the treatment of mammals in general, the preferred subject is humans. In determining an efficacious dose for human therapy, results of animal testing are frequently extrapolated and a correlation is assumed between animal test behavior and proposed human dosage. When a commercially employed standard is available, the dose level of the clinical candidate in humans is frequently determined by comparison of its performance with the standard in an animal test. For example, phenylbutazone is employed as a standard anti-inflammatory agent and is administered to humans at the rate of 100 to 400 mg. daily. It is assumed, then, that if compounds of the present invention have activity comparable to phenylbutazone in the test assay, that similar doses will provide comparable responses in humans.

Obviously, the physician will ultimately determine the dosage which will be most suitable for a particular individual, and it will vary with the age, weight and response of the particular patient as well as with the nature and extent of the symptoms and the pharmacodynamic characteristics of the particular agent to be administered. Generally, small doses will be administered initially, with a gradual increase in the dosage until the optimum level is determined. It will often be found that when the composition is administered orally, larger quantities of the active ingredient will be required to produce the same level as produced by a small quantity administered parenterally.

[Having full regard for the foregoing factors, an effective daily dosage of the compounds of the present invention in humans is approximately 0.1 to 1.0 g. per day, with a preferred range of about 0.2 to 0.8 g. per day in single or divided doses, or at about 3 to mg./kg. of body weight will eflectively alleviate inflammation in human subjects prone to said disorder. These values are illustrative, and there may, of course, be individual cases where higher or lower dose ranges are merited.

The following examples are provided solely for the purpose of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit or scope thereof.

EXAMPLE I 8,9 dihydro 2 (p methoxyphenyDdibenzo[3,4,7,8] cycloo'cta[1,2-d]imidazole (I: Z=--CH CH X, Y=H and R=p-CH OC H To a solution of 1.5 g. (6.4 mmoles) of 11,12-dihydrocycloocta[a,e]dibenzene-5,6-dione in 50 ml. of dry glacial acetic acid contained in a three-necked flask and under a nitrogen atmosphere is added 3.0 g. of ammonium acetate. To the resulting dark yellow solution is added, dropwise, 1.1 g. (7.7 mmoles) of p-methoxybenzaldehyde in 10 ml. of dry glacial acetic acid. The reaction mixture is heated to reflux overnight and is then cooled, poured into 300 ml. of ice-water and the pH adjusted to 7.0 by the addition of ammonium hydroxide solution. The resulting precipitate is filtered, dried and recrystallized from benzene, 385 mg., M.P. 318-320" C. A second recrystallization from benzene provided the analytical sample, M.P. 32l-323 C.

Analysis.Calcd. for C H N O (percent): C, 81.8; 11-1, 5.7; N, 8.0. Found (percent): C, 81.2; H, 5.9; N, 7.6.

6 EXAMPLE II Starting with 11,12-dihydrocyclo6'cta[a,e]dibenzene- 5,6-dione and the requisite aldehyde, and repeating the procedure of Example I, the following compounds are 8 EXAMPLE IV 8,9 dihydro 2 trifiuoromethyl 5,12 dichlorodibenzo- TABLE-Continued [3,4,'7,8]cyclooctal[1,2-d]imidazole (I: Z

A solution of 3.04 g. (10 mmoles) of 11,12-dihydro- 3,8-dichlorocyclo6cta[a,e]dibenzene-5,6-dione in 100 ml.

of anhydrous glacial acetic acid, under a nitrogen atmosphere, is treated with 4.7 g. of ammonium acetate followed by 4.3 g. (30 mmoles) of trifluoroacetaldehyde ethyl hemiacetal in 50 ml. of the same solvent. The resulting solution is heated to reflux for 3 hours, an additional 4.3 g. of the hemiacetal added and heating continued for 3 hours more. The reaction mixture is cooled, poured into a mixture of ice and water and the pH adjusted to 7 using concentrated ammonium hydroxide solution. The crude product is filtered, dried and purified by recrystallization several times from toluene.

EXAMPLE V Starting with the requisite 11,l2-dihydrocyclo6cta[a,e] dibenzene-5,6-dione and aldehyde, and following the pro- HHHHHHHHHHHHHHHHHHHHHHHH cedure of Example IV, the following tetracyclicimidazole analogs are synthesized:

HHHHHHHHHHHHHHHHHHHHHHHHH mm 2 1% win mm mnnm mmm HH Han dd NN me .71 dd ma ma a mmmmw. mo H fizm nm P. 2 H 33$? 0 i wmfi m wCFFCwm m m mmflscflFwwra wcaflcFFmcoc mmm-qFFflbcfl m acoaemppcocm pcp omm m ooceae mpooop pm mwmmwwwii sesam 111111..rrrrHHH HHHHHHHHHrrH rrrHHHHH CCCOGOBBBBacconwcoooccoccmnBomFmFmmiBBaccacom asseaease???a aaaaaaaaa7ma7.h1m71ww1e55em 6.6. fifiwazaawwwwmwww iiiiiirrrrrrrnur HHHHHHHHHHHHHHH FFFFOCcoococooCBBBBBBm oBFcmvccoccoococccoc eaaaaaaaarrLLrtaddaedosaanaaaaaaarrrrrrrr 1111111111111111111111111l11111111111111111 44 4 "Him m 4 0H EH 4 C 0 0 m mm 1.0. m E 4 m mowmHmN. ac mmmwomum mmocwmn a! AWHH Han un ed aw n H0- Ema HHHC m rHHO 1 l H O lC mm 1 F mmffi sfia e 0 beta a? Sa e CmymdvmmubCcCppacCalr ppomn. pmpflomm DCCCCPapw saaaaa aasaaaa "mam HHHHHH HHHHHHH 1 1 HH occooooooosoooFFmmmmw mFF mmcmmommmmmmmmco ewmv5nfmzw hozwp 7- whn w5555fifififlflw 6666d6fl555555554w a a a a lmwwmwwmwmwwwmwwww a a a m w mme. HHHHHHHHHHHHHHEHHHHHHH HHHHHHHHH coccoeoeecoecoeoecooocmw r ummmmmooec occo mwmmmwwmwmmmunnnnnnnnnmm nmmnnnnwmmnmmmmm TABLEContlnued X Y R x Y R.

11-011 7-CH 0 -CH 0 H i 28%;? 8 u-ongo v-ongo -ongoixirr 10-Br -CH3S 2-C5H4N ll-F -Br o-FC H IO-Bl 5-CH3S 4-C5H4N ll-F 7-Bl IJ-FCQH4 10-131 7-Br COHg IO-Br 7-Br m-HO2CCrH4 EXAMPLE VI TABLECoutlnued Z-trifluoromethyldibenzo[b,f]thiepin[4,5-d]imidazole X Y R (I: z=s; x, Y=H and R=CF X Y R H H O-CHsCaHq g g-ggag mgrlgsflr A mixture of 170mg. (0.7 mmole) of 10,11-dihydro- H H o-CHsOCaHr a pr t 4 dibenzo[b f]thiepin-10,l1-dione, 300 mg. (2.1 mmoles) H H m-CHB0C6H4 H 70H30 043106134 H H p-CH SCaH4 H 7-CH3O O-FCoH of trifl-uoroacetaldehyde ethyl hermacetal and 1.0 g. of H 40H CH SCUH H Cm ammonium acetate in 40 ml. of anhydrous glacial acetic H I Z g 3 H Cum acid is heated to the reflux temperature for one hour. H mm 08H H 4-F 3-C5H4N An additional 170 mg. of diketone and 300 mg. of hernr- H 3H8 pwmhficflm H 4-1 4-C5H4N acetal in 5 ml. of the same solvent are added and the H 4,0113 PFCGH, H 4-F P-CHQSCJI; refluxing continued for one more hour. The addrtlon is H 13410811, H 6-F CF: repeated again, and the mixture heated at reflux tempera- H 5-CH3 p-OIC H4 g 52 2; tures for 3 hours. The reaction mixture is cooled, poured H 5-CH: p-BrCaH4 H 6 F 3 B 4 H 5-0151 o-CH 000114 3006114 mto ice-water and the pH ad usted with ammonium hys a H 5 0H 0H 0 H H e F p HO2CCaH4 droxide to 7. The crude product 1s filtered, dried and re- H E 501133 FFCBHQ cr stallized from benzene, 300 mg., M.P. 255-257 C. 3 2 4 H S-CHzS 2-G5H4N Y Analysis.-Calcd. for C H N SF (percent): C, 60.4; H 5-01 p-HO2CCsH H, 2.8; N, 8.8. Found (percent): C, 60.4; H, 2.1; N, 8.6. 0 H 3H3 PHOZCCBH H 5-01 tit-010111 H 7-OH3 p-OH SG H H 541MB EXlAMPLE VII H mm $010111 H 5-01 0.2:,

0 H s-onao on. g gi Starting with 10,11-d1hydrod1benzo[b,f]th ep1n-l0,1l- H 5-CH3O 00H. H 5:CH3S H dione and the appropriate aldehyde and repeating the pro- H 7-01 O-FCsHq H 543mg 2 cedure of Example VI, the following compounds are pre- H 7-01 m-FCaH4 H MESS 343mm H 7-01 p-FCuH4 pared. H 7431 p (CHWNCUH H 5-CH3S 4-C5H4N H 5-CHzS on 2-phenyldibenzo [b,f]thiepin[4,5-d]imidazole, M.P. 312 11g zg jgfgi H 5.033s 00113506114 C., dec.; 4 H mflowoem H e-gms o-BrCaHx 2-(p-methoxyphenyl)d1benzo[b,f]th1ep1n[4,S-d]1m1dazo1e, H LEI CFK H 6- HaS mBlCsH4 M1 3000 c d H 4 Br CGHE H (i-CHaS m-(CHahNCsH; 2-(p-bromophenyl)dibenzo[b,f]thiepin[4,5-d]imidazole, H 54% 06115 g 3:35 5238 88 M.P. 334 C.,dec.; H 5-Br p-CH oC lL H 7431128 CFQ 2 2-(p-chlorophenylgdibenzo[b,f]thiepin[4,5-d11mrdaa0le, g g-g: Ia HaOQE H 7 CH3S 06H;

M.P. 323 C., ec.; a H v-onas o-OlOH 2-(3-pyridyl)dibenzo[ b,f]thiepin[4,5-d]imidazole, M.P. g 2'? g )2 u H 7-CH3S p-OlCqHr 230 C., dec.; H HmNCH4 H 7-CHaS p-OH C H 2-(p-carboxyphenyl)dibenzo[b,f]thiepin[4,5-d] H 060cm imidazole, M.P. 360 0.; and H em -clo H, 2-(pdimethylaminophenyDdibenzo[b,f]thiep1n[4,5-d]

imidazole, M.P. 321 C., dec.

Starting with the appropriately substituted 10,11-dihydrodibenzo[b,f]thiepin-10,1l-dione and requisite alde- 55 EXAMPLE IX hyde, and employing the procedure of Example VI, the following compounds are prepared:

2-phenyl-5, l l-dichlorodibenzo [b,f] thiepin [4,5-d] imidazole (I: Z=S; X, Y=Cl; R=C H A mixture of 3.08 (0.01 mole) of 2,8-dichloro-10,lldihydrobenzo[b,f]thiepin-10,1l-dione 7.0 g. of ammo- .nium acetate and 1.28 g. (0.012 mole) of benzaldehyde Employing the aforedescribed procedure of Example IX, and starting with the requisite ketone and aldehyde, the following analogs are synthesized:

13 EXAMPLE XIII Employing the carrageenin rat foot edema test as a measure of anti-inflammatory activity, the following representative tetracyclicimidazoles were found to have the indicated activity at the specified dose:

Activity Percent Dose, mg./ X Y Z R inhibition kg., p.o.

H H -CHzCHr- CaHs 46 33 H H --CH2CHz p-C1CsH4 19 83 H H' -CH2CH2 3-C2H4N 21 33 H H -CHzCHzp-CHaSCaH; 20 33 H H -CH2CH2- a 20 33 H H CHzCH2 D-HOZCCsHI 11 33 H H 6 5 19 as H H s -omomm as as H H S pBrCaH4 13 33 H H S 3-CaH4N 25 33 H S S CF; 36 33 H B S CFa 15 10 H s s p-HOzCCuH4 I 28 as Phenylhnta'mne 55 33 EXAMPLE XIV 8,9-dihydro-2- (p-methoxyphenyl) dib enzo [3 ,4,7,8] cycloocta[1,2-d]imidazole hydrochloride To a warm solution of 3.5 g. (0.01 mole) of 8,9-di- 35 'hydro 2 (p-methoxyphenyl)dibenzo[3,4,7,8]cyclo6cta- [l,2-d]imidazole in 40 ml. of absolute methanol is added gaseous hydrogen chloride until the resulting precipitates of the hydrochloride salt ceases to form. The suspension is cooled in iceand the precipitate filtered and dried. An equal volume of diethyl ether is added to the filtrate, re sulting in the precipitation of a second crop of the desired hydrochloride salt. The two fractions are combined and recrystallized from ethanol.

To this suspension, various sweeteners and flavorants are added to improve the palatability of the suspension. The suspension containsapproximately 100 mg. of effec tive agent per milliliter.

EXAMPLEXVI Solid dispersion A solid dispersion containing 20% Z-tri'fiuoromethyldibenzo[b,f]thiepin[4,5-d]imidazole and 80% polyethylene glycol 6000 (PEG 6000) is prepared by adding in small portions and with constant stirring 100 g. of the imidazole to 500 g. of PEG 6000 heated to C. When all the compound is added, the melt is flash cooled by cooling in an ice bath and the solidified product reduced to a fine powder and passed through a 100 mesh sieve.

14 The material is not passing through 1s recycled through the melting process.

EXAMPLE XVII Tablets A tablet base is prepared by blending the following ingredients in the proportion by weight indicated:

Sucrose, U.S.P. 80.3 Tapioca starch 13.2 Magnesium stearate 6.5

EXAMPLE XVIII Capsules A blend is prepared containing the following ingredients:

Calcium carbonate, U.S.P. 17.6 Dicalcium phosphate 18.8 Magnesium trisilicate, U.S.P 5.2 Lactose, U.S.P. 5.2 Potato starch 5.2 Magnesium stearate A 0.8

Magnesium stearate B 0.35

To this blend is added suflicient 8,9-dihydro-2-phenydibenzo[3,4,7,8]cyclo5cta[1,2-d]imidazole to provide capsules containing 50, 200 and 400 mg. of active ingredient per capsule. The compositions are tilled into conventional hard gelatin capsules in the amount of 500 mg. per capsule.

PREPARATION A (a) 5,6,11,12 tetrahydrodibenzo [a,e] cyclooctene-5,6- dione is back-washed with a saturated sodium bicarbonate solution and dried over calcium sulfate. The calcium sulfate is filtered and the-filtrate evaporated to dryness, leaving a yellow semi-solid, which on recrystallization from ethanol I provided the desired product in three crystallization fractions, 3.8 g.) 21.3 g. and'3.5 g.) M.P.s ISO-132 C.,

129 C. and ISO-131 C., respectively. The three crops are combined and used without further purification.

Leonard et al., J. Am. Chem. Soc., 77, 5078 (1955), reports melting point of 131-132 C. for this material, prepared by a different method.

(b) The following 5,6,11,12-tetrahydrodibenzo[a,e,] cyclooctene-5,6-diones, not previously reported in the 15 a v. 16 chemical literature, are synthesized by the selenium dithiepin-lO-ll-diones, not previously known in the literaoxide oxidation of the correspondingmonoketone: v ture, are prepared:

The following cycloocta[a,e]dibenzen-5(6H) ones, previouly unreported in the chemical literature, are prepared according to the-procedure as taught by Leonard et al., J. Am. Chem. Soc.-, 77, 5078 (1955); and comprises cyclization of the appropriate 2-phenylethylphenylacetic acid with polyphosphoric acid at steam bath temperatures for 5-6 hours:

7 S e n m mm. mm: at me H HH11L1HHHHH iiinnrr W CCCCCCCCCCBBCFCCCCCBB 5 aarnaaaertaazaaaeeeae m e C, m saw .2. nema. N e iillrrrrHH HH HHHHm .m FCCCOBBBBCCFFCCFCCCCF I d eeewiwweewweseeswwwr T m ra .2; m steleii w A a nun H irrrnnnnnnn H 10 000 GFFOCBBBC CC00 0 M b 1&1 eraaeraaaserrazzzz c P W m 32mm d mwmmwg. m .1 nnnnnnnnnnnnnnnewwrwss M 1 t 1 1 0 5 0 5 m 2 2 no 3 3:; 3. at saw HHHH HHHH H HH co0cFnFFFmmmmmmccccnmmmcrnca nyowLLowomm:.k%-m-9 .m-nramnmnoaumvowbla walqul amw awmww as. a a wwmw HHHHHHHH iimmnnnnmnnnn obcoccocmwmeoccooebccoocboc 777889987 79.1779911777777999 a a awwww "masks. HHHHHHHH llllrrrrHHHHHrr CCCCCCCOF FFOOOC BBC00C raaeraaer2aeraa+12a+r2s4a11 PREPARATION B (a) 10,1l-dihydrodibenzo[b,f]thiepin-l0,1 l-dione A mixture of 50 mg. (0.22 mmole) of 10,1l-dihydrodibenzo[b,f]thiepin-10 one and 27: mg. (0.24 mmole) of selenium dioxide in 15 ml heated at 80 C.

of dry glacial acetic acid is until a solution is effected. The reaction C. and maintained for tion mixture is filtered, poured into water and extractedwith ethyl acetate. The organic layer temperature is then raised to 110. 2 hours. The reac is concentrated to dryness and the semi-solid triturated with hot benzene. Removal of the benzene provides the desired product as a yellow solid, 38 mg., M.P. 116f126 C, Theanalytical sampleis triturated'with diethyl ether, 7 M.P.120-126 C. a I Analysis.-Calcd. for C H O S (percent) t C, 70.00; H, 3.3. Found (percent): C, 70.0; H, 3.5.

(b) Following the above described oxidation procedure I the following substituted 10,11 dihydrodibenzo[b,f]

PREPARATION D 10,1-dihydrodibenzo [b,1f]thiepin-1O-ones Employing the procedure as taught by Iilek et al., Monatsh. Chem, 96, 201 (1965 the following dibenzo- [b,f]thiepin-10-ones are prepared via cyclization of the requisite 2-phenylthiophenylacetic acid using polyphosphoric acid at 125 C. for 1-2 hours:

2-phenylethylphenylacetic acids The above-mentioned Z-phenylethylphenylacetate acids are synthesized according to the sequence of reactions as taught by Leonard et al., J. Am. Chem. Soc., 77, 5078 (1955), wherein, starting with 2-phenylethylbenzoic acid the following reactions are effected:

- zCz u s omen CH;Br

(cum-Q H280, (cum-Q -CH1CN 011300211 cmcouzr For convenience, the intermediate products are not purified or characterized, but used directly in the next step of the reaction sequence.

Employing the above-described reaction series, and

18 viously unreported Z-phenylethylphenylacetic acids, are prepared:

PREPARATION F 2-phenylthiophenylacetic acids The requisite 2-phenylthiophenylacetic acids employed as intermediates leading to the products of the instant invention are prepared by the sequence of reactions as taught by Jilek et al., Monatsh, Chem., 96, 201 (1965) and Protiva et al., Czech. Pat. 121,337 (C.A. 68, 105247t (1968) and comprises conversion of a 2-phenylthiobenzoic acid to the corresponding phenylacetic acid depicted below.

Y cm The intermediates are not purified or characterized, but are used directly in the next reaction. In the abovestarting with the requisite benzoic acid, the following, predescribed manner, the following Z-phenylthiophenylacetic acids, not previously, described in the chemical literature,

are synthesized:

PREPARATION G 2-phenylethylbenzoic acids The following 2-pheny1ethylbenzoic acids, not previously reported in the chemical literature, are prepared according to the procedure of Cope et al., J. .Am. Chem. Soc., 73, 1676 (1951) and comprises the red phosphorushydriodic acid reduction of the corresponding benzalphthalide:

s 2 a Y 4 2 omon4 l PREPARATION -H 2-phenylthiebenzoic acids The following Z-phenylthiobenzoic acids, previously unreported in the chemical literature, are synthesized from the commercially available or known thiophenols and o-halobenzoic acids according to the method-of Protiva et al., Czech. Pat. 121,337 (C.A. 68, 105247t 1968) and 20 Mahishi et al., J. KarnatakUniv., 2, 50 (1957) (C.A. 53, 14l01h; 1959).

PREPARATION I Benzalphthalides What is claimed is:' 1. A compound selected from those of the formula:

21 22 and the pharmaceutically acceptable acid addition salts 4. A compound of claim 2 wherein R is 3-pyridy1. thereof, wherein: 5. A compound of claim 2 wherein R is trifluoromethy].

6. A compound of claim 2 wherein R is p-carboxy- Z is sulphur; X and Y are each selected from the group consisting of hydrogen, methyl, methoxy, fluorine, chlorine, bromine, 5 References Clted and methylthio; and Steck, I. Am. Chem. 800., vol. 65, pp. 452-56 (1943). R is selected from the group consisting of trifluoromethyl,

pyridyl, naphthyl and phenyl and substituted phenyl HARRY MOATZ= PflmarY Examlnel wherein said substituent is selected from the group consisting of methyl, methoxy, fluorine, chlorine, bro- 19 mine, dimethylamino, carboxy and methylthio. 26( 327 B, 346,2 R, 465 R, 465 F, 465 G, 469, 470, h 2. A compound of claim 1 wherein X and Y are each 473 R, 515, 51 520, 590; 424.4 3, 273; 2 0 309 ydrogen.

3. A compound of claim 2 wherein R is p-methoxyphenyl. 15

phenyl. 

